# Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

> **NCT03801434** · PHASE2 · RECRUITING · sponsor: **William Shomali** · enrollment: 10 (estimated)

## Conditions studied

- BCR-JAK2 Fusion Protein Expression
- Blasts 20 Percent or Less of Peripheral Blood White Cells
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- Blasts More Than 5 Percent of Peripheral Blood White Cells
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Chronic Eosinophilic Leukemia, Not Otherwise Specified
- Eosinophilia
- Hepatomegaly
- Hypereosinophilic Syndrome
- JAK2 Gene Mutation
- Splenomegaly
- TEL-JAK2 Fusion Protein Expression

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03801434
- **Lead sponsor:** William Shomali
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-15
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801434, "Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03801434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*